Now, the growing buzz around the use of GLP-1 medications like Ozempic to treat alcohol use disorder finally has new clinical study results that support this theory. (Prior studies have simply found a link between taking a GLP-1 receptor agonist and drinking less—but didn’t go so far as to actually prove that the medications caused people to drink less.

A small semaglutide trial suggests the medicine's suppression of appetite may extend to alcohol, but larger tests are needed to establish a conclusive benefit.